Medigrowth Australia

Medigrowth is an Australian medicinal cannabis biotechnology company dedicated to the research, development, and commercialization of pharmaceutical-grade cannabinoid therapies. Based in Geelong, Victoria, the company maintains a strategic research partnership with Deakin University to conduct clinical trials focusing on pediatric autism and chronic pain management. Medigrowth operates a vertically integrated model that spans genomic research, cultivation, and the distribution of its proprietary Haiku brand of medicinal cannabis products. The company aims to bridge the gap between traditional medicine and cannabinoid science through rigorous evidence-based clinical data. Their products are currently available to patients in Australia via the Special Access Scheme and Authorized Prescriber pathways.